Janney Capital


Medivation Remains One Of Our Top Ideas, Says Janney Capital

In a research report released August 8, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Medivation Inc. (MDVN) with a $110 …

Janney Capital Reiterates Buy On Amicus Therapeutics Following Post 2Q14 Updates

 In a research note published August 8, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Amicus Therapeutics (FOLD) with a $5 …

NPS Pharmaceuticals Shares Remain Undervalued, Says Janney Capital

In a research report released yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NPSP) with a $37 fair …

Janney Reiterates Buy On Medivation Following Astellas’ Xtandi Sales Report; Sees $110 Fair Value

In a research report issued Friday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Medivation Inc. (MDVN) with a $110 fair value estimate, following Medivation’s partner Astellas (ALPMY) second quarter results …

Aegerion Shares Remain Undervalued Given The Significant Market Opportunity, Says Janney Capital

In a research report released yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Aegerion Pharmaceuticals (AEGR) on the heels of …

Janney Capital Maintains Buy On Raptor Pharmaceutical, Sees 34% Upside

In a research note released this morning, Janney Capital analyst Kimberly Lee maintained a Buy rating on Raptor Pharmaceutical (RPTP) with a $17 …

Janney Capital Maintains Buy On Vertex Ahead Of 2Q:14 Earnings Results

In a research report published today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX) with a $110 price …

Janney Capital Maintains Neutral On PDL Biopharma; $8 PT

In a research note released today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on PDL Biopharma (PDLI) with a $8 price target, ahead of the upcoming …

NPS Pharmaceuticals: All Eyes Remain On Gattex Launch And Natpara Adcom Meeting, Says Janney

In a research note released this morning, Janney Capital analyst Kimberly Lee maintained a Buy rating on NPS Pharmaceuticals, Inc (NPSP) with a …

Medivation Remains One Of Our Top Ideas For 2014, Says Janney

In a research report issued today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Medivation Inc. (MDVN) with a $110 price target, which …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts